Natalie D. Eddington PhD, FAAPS, FCP

Dr. Eddington earned a BS in pharmacy from Howard University and a PhD in pharmaceutical sciences from UMSOP. After completion of her PhD, Dr. Eddington was appointed as the clinical director of new drug development at Pfizer, Inc. After three years at Pfizer, Dr. Eddington began her academic career at UMSOP as an assistant professor, where she also served as chair of the Department of Pharmaceutical Sciences and director of the Pharmacokinetics-Biopharmaceutics Laboratory.

Dr. Eddington is a nationally known expert in drug delivery and pharmacokinetics. Her research focuses on various medications used in the treatment of cancer, epilepsy, arthritis, and drugs of abuse, and on understanding the role of biopharmaceutics and pharmacokinetics in elucidating the underlying mechanisms important in optimizing drug therapy. Her research has been supported by the National Institutes of Health (NIDA, NIBIB, NIMH, NCI), the U.S. Food and Drug Administration (FDA), the Department of Defense, and the pharmaceutical industry. Dr. Eddington is the author of more than 125 publications and has given more than 150 presentations and 100 invited lectures on topics related to pharmacokinetics, pharmacodynamics, transporter processes, and academic pharmacy.